A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413)

on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG)

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In January 2017, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group commenced a randomized Phase III trial to confirm the clinical benefit of lobe-specific nodal dissection for clinical Stage I-II non-small cell lung cancer. The primary endpoint is overall survival, and the main objective is to confirm the non-inferiority of lobe-specific in comparison to systematic nodal dissection with regard to lobectomy. The secondary endpoints are relapse-free survival, %local recurrence, %regional lymph node recurrence, operation time, blood loss, length of hospitalization, duration of chest tube placement and adverse events. A total of 1700 patients will be accrued from 44 Japanese institutions within 5 years. This study is the first and large prospective trial to evaluate whether the difference in the area of nodal dissection affects the overall survival of patients with relatively early-stage non-small cell lung cancer. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000025530.

Original languageEnglish
Pages (from-to)190-194
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume48
Issue number2
DOIs
Publication statusPublished - 2018 Feb 1

    Fingerprint

Keywords

  • Lobe-specific
  • Lymph node dissection
  • Non-small-cell lung cancer
  • Randomized Phase III study
  • Systematic

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this